BioHarvest

Company Overview

Snapshot

Founded in January 2007 by Zaki Rakib and Yochi Hagay, BioHarvest operates with 11–50 employees. The company has raised a total of $13.37 million across 7 funding rounds. In November 2024, BioHarvest Sciences began trading on the Nasdaq Global Market, marking a significant milestone for the company.

Business overview

BioHarvest develops functional biofood products using proprietary technology that preserves plant phytochemicals in their natural state for optimal bioavailability and efficacy. Its flagship product, VINIA, is a red grape powder offering the benefits of red wine without associated sugars, calories, or alcohol. The company utilizes a clean hydroponic production process, free from solvents, GMOs, and chemical residues. BioHarvest also applies its biofarming technology to cannabis plants to produce cannabinoids without growing the full plant, serving the nutraceutical, pharmaceutical, and medical cannabis markets.

Strategic signal

In January 2025, BioHarvest Sciences Inc. announced its strategic positioning for a "legacy year" in 2025, emphasizing sustainability, longevity, and plant-based innovation. This signals a continued focus on product expansion, including new beverage options and VINIA Super-Chews, and strengthening its CDMO services through partnerships like the one with Tate & Lyle for sugar-free sweeteners. This indicates a strong growth trajectory and a commitment to expanding its market presence and product portfolio in the health and wellness industry.

Company Intelligence Q&A

What was a significant financial milestone for BioHarvest in late 2024?

In November 2024, BioHarvest Sciences Inc. began trading its shares on the Nasdaq Global Market under the ticker symbol BHST. This move was intended to enhance its public profile, improve liquidity, and broaden its shareholder base.

What strategic partnership did BioHarvest announce in January 2025?

In January 2025, BioHarvest announced a key partnership with Tate & Lyle to develop sugar-free sweeteners, aiming to expand its CDMO services and product offerings.

What was the nature of BioHarvest's private placement in June 2024?

In June 2024, BioHarvest Sciences announced a private placement to raise up to $5 million.

What was the focus of BioHarvest's private placement in February 2023?

In February 2023, BioHarvest Sciences announced a private placement of up to CAD $8 million in convertible notes. The funds were primarily allocated to support growth in its polyphenols/antioxidants vertical and its R&D program for Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry.

What clinical study did BioHarvest announce in February 2023?

In February 2023, BioHarvest Sciences announced a collaboration with the International Neurorehabilitation Institute (INI) to conduct a clinical trial. This study aims to assess the capacity of its RGC composition to promote eye health, specifically evaluating its impact on multiple sclerosis-related optic neuritis.